Enanta
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Enanta and other ETFs, options, and stocks.About ENTA
Enanta Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. It produces clinical candidates which targets respiratory syncytial virus (RSV), hepatitis B virus (HBV), and non-alcoholic steatohepatitis (NASH) diseases.
CEOJay R. Luly
CEOJay R. Luly
Employees131
Employees131
HeadquartersWatertown, Massachusetts
HeadquartersWatertown, Massachusetts
Founded1995
Founded1995
Employees131
Employees131
ENTA Key Statistics
Market cap349.36M
Market cap349.36M
Price-Earnings ratio-2.62
Price-Earnings ratio-2.62
Dividend yield—
Dividend yield—
Average volume2.65M
Average volume2.65M
High today$11.46
High today$11.46
Low today$10.62
Low today$10.62
Open price$11.27
Open price$11.27
Volume323.80K
Volume323.80K
52 Week high$15.34
52 Week high$15.34
52 Week low$4.09
52 Week low$4.09
ENTA News
Simply Wall St 4d
Enanta Pharmaceuticals Is Up 33.3% After Positive Phase 2b RSV Results Propel Zelicapavir ForwardIn late September 2025, Enanta Pharmaceuticals announced positive topline results from its Phase 2b trial of zelicapavir for treating respiratory syncytial viru...
TipRanks 6d
Enanta Pharmaceuticals Announces Public Stock OfferingElevate Your Investing Strategy: Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to...
TipRanks 6d
Enanta upgraded to Buy from Hold at JefferiesJefferies analyst Akash Tewari upgraded Enanta (ENTA) to Buy from Hold with a price target of $20, up from $14. Elevate Your Investing Strategy: Take advantag...
Analyst ratings
86%
of 7 ratingsBuy
85.7%
Hold
14.3%
Sell
0%
People also own
Based on the portfolios of people who own ENTA. This list is generated using Robinhood data, and it’s not a recommendation.